Restriction of retroviral replication by APOBEC3G/F and TRIM5α

Trends in Microbiology

Volumn 16, Issue 12, 2008, Pages 612-619

  Huthoff, Hendrik ^a   Towers, Greg J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DNA; INTERFERON; MEMBRANE PROTEIN; PROTEASOME; TRIMCYP PROTEIN; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA;

ANTIVIRAL ACTIVITY; DNA BINDING; DNA RESTRICTION; DNA SYNTHESIS; HUMAN; INNATE IMMUNITY; MOLECULAR EVOLUTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETROVIRUS; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CARRIER PROTEINS; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV-1; HUMANS; MODELS, MOLECULAR; RETROVIRIDAE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 56949089824     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2008.08.013     Document Type: Review

References (79)

1. Kaiser J. AIDS research: review of vaccine failure prompts a return to basics. Science 320 (2008) 30-31
2. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
3. Harris R.S., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
4. Sheehy A.M., et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
5. Yu X., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
6. Holmes R.K., et al. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem. Sci. 32 (2007) 118-128
7. Bishop K.N., et al. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 (2004) 1392-1396
8. Liddament M.T., et al. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
9. Wiegand H.L., et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
10. Zheng Y.H., et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 6073-6076
11. Chen K.M., et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452 (2008) 116-119
12. Newman E.N., et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
13. Turelli P., et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303 (2004) 1829
14. Esnault C., et al. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34 (2006) 1522-1531
15. Hulme A.E., et al. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390 (2007) 199-205
16. Chiu Y.L., et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15588-15593
17. Holmes R.K., et al. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282 (2007) 2587-2595
18. von Schwedler U., et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67 (1993) 4945-4955
19. Iwatani Y., et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35 (2007) 7096-7108
20. Anderson J.L., and Hope T.J. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 375 (2008) 1-12
21. Chiu Y.L., et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435 (2005) 108-114
22. Soros V.B., et al. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3 (2007) e15
23. Miyagi E., et al. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81 (2007) 13346-13353
24. Schumacher A.J., et al. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82 (2008) 2652-2660
25. Janini M., et al. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J. Virol. 75 (2001) 7973-7986
26. Kieffer T.L., et al. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 79 (2005) 1975-1980
27. Vartanian J.P., et al. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3092-3096
28. Simon V., et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1 (2005) e6
29. Pillai S.K., et al. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5 (2008) 26
30. Mulder L.C., et al. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5501-5506
31. Deforche K., et al. Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J. Comput. Biol. 14 (2007) 1105-1114
32. Berkhout B., and de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18 (2004) 1861-1863
33. Stremlau M., et al. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
34. Towers G., et al. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12295-12299
35. Cowan S., et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11914-11919
36. Nisole S., et al. TRIM family proteins: retroviral restriction and antiviral defence. Nat. Rev. Microbiol. 3 (2005) 799-808
37. Yamauchi K., et al. Ubiquitination of E3 ubiquitin ligase TRIM5alpha and its potential role. FEBS J. 275 (2008) 1540-1555
38. Diaz-Griffero F., et al. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 369 (2007) 400-410
39. Mische C.C., et al. Retroviral restriction factor TRIM5alpha is a trimer. J. Virol. 79 (2005) 14446-14450
40. Yap M.W., et al. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15 (2005) 73-78
41. Passerini L.D., et al. Retroviral restriction factors Fv1 and TRIM5{alpha} act independently and can compete for incoming virus before reverse transcription. J. Virol. 80 (2006) 2100-2105
42. Si Z., et al. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7454-7459
43. Ylinen L.M., et al. Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. J. Virol. 80 (2006) 7332-7338
44. Schaller T., et al. An active TRIM5 in rabbits indicates an antiviral common ancestor for mammalian TRIM5 proteins. J. Virol. 81 (2007) 11713-11721
45. Sawyer S.L., et al. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2832-2837
46. Keckesova Z., et al. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10780-10785
47. Newman R.M., et al. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19134-19139
48. Wilson S.J., et al. Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J. Virol. 82 (2008) 7243-7247
49. Sayah D.M., et al. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 (2004) 569-573
50. Nisole S., et al. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13324-13328
51. Zhang F., et al. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353 (2006) 396-409
52. Wilson S.J., et al. Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3557-3562
53. Virgen C.A., et al. Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3563-3568
54. Brennan G., et al. TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3569-3574
55. Newman R.M., et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog. 4 (2008) e1000003
56. Liao C.H., et al. A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS 21 Suppl 8 (2007) S19-S26
57. Yap M.W., et al. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J. Virol. 80 (2006) 4061-4067
58. Schaller T., et al. Fusion of cyclophilin a to fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J. Virol. 81 (2007) 10055-10063
59. Bosco D.A., et al. Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5247-5252
60. Berthoux L., et al. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14849-14853
61. Keckesova Z., et al. Cyclophilin A renders HIV-1 sensitive to old world monkey but not human TRIM5a antiviral activity. J. Virol. 80 (2006) 4683-4690
62. Stremlau M., et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5514-5519
63. Wu X., et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7465-7470
64. Campbell E.M., et al. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J. Cell Biol. 180 (2008) 549-561
65. Sakuma R., et al. Alpha interferon enhances TRIM5{alpha}-mediated antiviral activities in human and rhesus monkey cells. J. Virol. 81 (2007) 10201-10206
66. Ylinen L.M., et al. Differential restriction of HIV-2 and SIVmac by TRIM5alpha alleles. J. Virol. 79 (2005) 11580-11587
67. Sakuma R., et al. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat.Med. 13 (2007) 631-635
68. Zhang F., et al. No effect of endogenous TRIM5alpha on HIV-1 production. Nat. Med. 14 (2008) 235-236
69. Barr S.D., et al. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 4 (2008) e1000007
70. Uchil P.D., et al. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4 (2008) e16
71. Hatziioannou T., et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314 (2006) 95
72. Kamada K., et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16959-16964
73. van Manen D., et al. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 4 (2008) e18
74. Almond N., et al. Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. J. Gen. Virol. 78 (1997) 1919-1922
75. Stebbings R., et al. CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus. J. Virol. 79 (2005) 12264-12272
76. Neil S.J., et al. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008) 425-430
77. Johnson R.P., et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73 (1999) 4952-4961
78. Berry, N. et al. Resistance to superinfection of a vigorously replicating uncloned stock of Simian Immunodifciency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J. Gen. Virol. (in press)
79. Randall R.E., and Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89 (2008) 1-47